Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 8/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21379664 | 0.88 | XDH (0.38) | MEN1KMT2ATHRBMAPTALDH1A1 | |
| SCHEMBL19783662 | 0.85 | THRB (0.45) | MEN1KMT2ATHRBDPP4MAPT | |
| SCHEMBL438293 | 0.84 | NPC1 (0.55) | MEN1KMT2ATHRBDPP4MAPT | |
| SCHEMBL19782938 | 0.84 | KMT2A (0.55) | MEN1KMT2ATHRBMAPTALDH1A1 | |
| SCHEMBL17128365 | 0.82 | KMT2A (0.60) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL16533516 | 0.77 | MEN1 (0.46) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL13255535 | 0.75 | ALDH1A1 (0.43) | MEN1KMT2ADPP4MAPTALDH1A1 | |
| SCHEMBL19782944 | 0.75 | DPP4 (0.36) | KMT2ADPP4MAPTALDH1A1MAPK1 | |
| SCHEMBL13652346 | 0.72 | KMT2A (0.54) | MEN1KMT2ATHRBMAPTALDH1A1 | |
| SCHEMBL19783367 | 0.72 | LMNA (0.36) | MEN1KMT2AMAPTMAPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-03 | — | — | US | disclosed |
| US-20190292176-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BISTOL MYERS SQUIBB COMPANY (US) | 2019-09-26 | — | — | US | disclosed |
| WO-2018013774-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292176-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | F2, F2RL3, PF4 | MEN1 1767/4885KMT2A 2420/4885THRB 845/4885 |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | F2, F2RL3, F12 | MEN1 1492/4885KMT2A 2390/4885THRB 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.